A phase II trial of chlorambucil in non-small cell lung cancer

A phase II trial of chlorambucil in non-small cell lung cancer

A Phase II trial of high-dose chlorambucil at 108 mg/m2 was undertaken in non-small cell lung cancer. No complete or partial objective responses were observed, and significant toxicity, including nausea, vomiting, and seizures, was noted. Chlorambucil at this dose and schedule of administration is n...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of clinical oncology 1987-12, Vol.10 (6), p.515-516
Hauptverfasser: GENTILE, P. S, WOODCOCK, T. M, BLUMENREICH, M. S, EPREMIAN, B. E, SEEGER, J, SHETH, S. P, HAMM, J. T, SHERRILL, E. J, ALLEGRA, J. C
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Antineoplastic agents
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - drug therapy
Chemotherapy
Chlorambucil - adverse effects
Drug Evaluation
Female
Humans
Lung Neoplasms - drug therapy
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A Phase II trial of high-dose chlorambucil at 108 mg/m2 was undertaken in non-small cell lung cancer. No complete or partial objective responses were observed, and significant toxicity, including nausea, vomiting, and seizures, was noted. Chlorambucil at this dose and schedule of administration is not recommended for the treatment of non-small cell lung cancer.
ISSN:0277-3732
1537-453X
DOI:10.1097/00000421-198712000-00011